EA201892745A1 - Фосфорамидатные производные нуклеозида в качестве противораковых агентов - Google Patents

Фосфорамидатные производные нуклеозида в качестве противораковых агентов

Info

Publication number
EA201892745A1
EA201892745A1 EA201892745A EA201892745A EA201892745A1 EA 201892745 A1 EA201892745 A1 EA 201892745A1 EA 201892745 A EA201892745 A EA 201892745A EA 201892745 A EA201892745 A EA 201892745A EA 201892745 A1 EA201892745 A1 EA 201892745A1
Authority
EA
Eurasian Patent Office
Prior art keywords
nucleoside
derivatives
treatment agents
phosphoramidate derivatives
cladribine
Prior art date
Application number
EA201892745A
Other languages
English (en)
Other versions
EA036409B1 (ru
Inventor
Хью Гриффит
Микаэла Серпи
Магдалена Слюсарчик
Original Assignee
НУКАНА ПиЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by НУКАНА ПиЭлСи filed Critical НУКАНА ПиЭлСи
Publication of EA201892745A1 publication Critical patent/EA201892745A1/ru
Publication of EA036409B1 publication Critical patent/EA036409B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Настоящее изобретение относится к производным кладрибина. Соединения представляют собой фосфорамидатные производные, в которых фосфорамидатный фрагмент находится по 3'-гидроксильной группе кладрибина. Настоящее изобретение также относится к фармацевтическим составам производных кладрибина и их применению в способах лечения. Соединения являются пригодными в лечении рака.
EA201892745A 2016-06-01 2017-05-31 Фосфорамидатные производные нуклеозида в качестве противораковых агентов EA036409B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1609601.8A GB201609601D0 (en) 2016-06-01 2016-06-01 Phosphoramidate compounds
PCT/GB2017/051549 WO2017207986A1 (en) 2016-06-01 2017-05-31 Phosphoramidate nucleoside derivatives as anticancer agents

Publications (2)

Publication Number Publication Date
EA201892745A1 true EA201892745A1 (ru) 2019-05-31
EA036409B1 EA036409B1 (ru) 2020-11-06

Family

ID=56410850

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892745A EA036409B1 (ru) 2016-06-01 2017-05-31 Фосфорамидатные производные нуклеозида в качестве противораковых агентов

Country Status (26)

Country Link
US (2) US10906929B2 (ru)
EP (1) EP3464309B1 (ru)
JP (2) JP7025351B2 (ru)
KR (1) KR20190015353A (ru)
CN (1) CN109195981A (ru)
AU (1) AU2017273117B2 (ru)
BR (1) BR112018074961A2 (ru)
CA (1) CA3025440A1 (ru)
CL (1) CL2018003404A1 (ru)
DK (1) DK3464309T3 (ru)
EA (1) EA036409B1 (ru)
ES (1) ES2801448T3 (ru)
GB (1) GB201609601D0 (ru)
HR (1) HRP20200983T1 (ru)
HU (1) HUE051335T2 (ru)
IL (1) IL263121B (ru)
MX (1) MX2018014859A (ru)
MY (1) MY198880A (ru)
PH (1) PH12018502606A1 (ru)
PL (1) PL3464309T3 (ru)
PT (1) PT3464309T (ru)
SA (1) SA518400552B1 (ru)
SG (1) SG11201810018TA (ru)
SI (1) SI3464309T1 (ru)
WO (1) WO2017207986A1 (ru)
ZA (1) ZA201807652B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
ES2742167T3 (es) 2014-11-28 2020-02-13 NuCana plc Nuevos derivados éster 2' y/o 5' de fosforamidato de aminoácidos de la 3'-desoxiadenosina como compuestos anticancerígenos
SI3464271T1 (sl) 2016-05-31 2020-10-30 Kalvista Pharmaceuticals Limited Derivati pirazola kot inhibitorji plazemskega kalikreina
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
DK3716952T3 (da) 2017-11-29 2022-03-14 Kalvista Pharmaceuticals Ltd Doseringsformer omfattende en plasmakallikrein-inhibitor
GB201720279D0 (en) 2017-12-05 2018-01-17 Nucana Biomed Ltd Anticancer compounds
US20200399295A1 (en) * 2018-03-09 2020-12-24 Medivir Ab Cancer treatment with (2,2-bishydroxymethyl) methylenecyclopropane nucleotides
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
CN110845560B (zh) * 2019-11-21 2021-08-24 广东中科药物研究有限公司 苯丙氨酸酰胺化的核苷酸衍生物及其制备方法与应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002223939A1 (en) * 2000-07-13 2002-02-05 Micrologix Biotech Inc. Synthesis and antiviral evaluation of nucleic acid based (NAB) libraries
EP1827460A4 (en) 2004-12-09 2012-03-14 Univ Minnesota NUCLEOSIDE WITH ANTIVIRAL AND ANTI-CANCER EFFECT
GB0505781D0 (en) 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
KR20110120886A (ko) 2009-01-09 2011-11-04 유니버시티 칼리지 오브 카디프 컨설턴트 리미티드 바이러스 감염 치료용 구아노신 뉴클레오사이드 화합물의 포스포라미데이트 유도체
US20120070411A1 (en) 2010-09-22 2012-03-22 Alios Biopharma, Inc. Substituted nucleotide analogs
US9156874B2 (en) * 2011-01-03 2015-10-13 Nanjing Molecular Research, Inc. Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs
CA2828326C (en) * 2011-03-01 2019-05-07 Nucana Biomed Limited Phosphoramidate derivatives of 5 - fluoro - 2' - deoxyuridine for use in the treatment of cancer
US9156872B2 (en) * 2011-04-13 2015-10-13 Merck Sharp & Dohme Corp. 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2015038596A1 (en) 2013-09-11 2015-03-19 Emory University Nucleotide and nucleoside compositions and uses related thereto
EP3074411A2 (en) 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC Nucleotides for the treatment of liver cancer
WO2015181624A2 (en) * 2014-05-28 2015-12-03 Idenix Pharmaceuticals, Inc Nucleoside derivatives for the treatment of cancer
MX2016015629A (es) 2014-06-25 2017-08-02 Nucana Biomed Ltd Formulacion que comprende un profarmaco de gemcitabina.
ES2742167T3 (es) * 2014-11-28 2020-02-13 NuCana plc Nuevos derivados éster 2' y/o 5' de fosforamidato de aminoácidos de la 3'-desoxiadenosina como compuestos anticancerígenos
CR20170594A (es) 2015-06-09 2018-04-27 Abbvie Inc Moduladores de receptor nuclear
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds

Also Published As

Publication number Publication date
CN109195981A (zh) 2019-01-11
EP3464309B1 (en) 2020-06-10
US10906929B2 (en) 2021-02-02
PH12018502606A1 (en) 2019-10-21
EP3464309A1 (en) 2019-04-10
ZA201807652B (en) 2021-05-26
WO2017207986A1 (en) 2017-12-07
IL263121A (en) 2018-12-31
KR20190015353A (ko) 2019-02-13
MY198880A (en) 2023-10-02
JP2019517510A (ja) 2019-06-24
HRP20200983T1 (hr) 2020-12-11
GB201609601D0 (en) 2016-07-13
US20210130387A1 (en) 2021-05-06
AU2017273117A1 (en) 2018-12-06
ES2801448T3 (es) 2021-01-11
DK3464309T3 (da) 2020-06-29
MX2018014859A (es) 2019-03-07
PT3464309T (pt) 2020-06-23
PL3464309T3 (pl) 2020-10-19
SI3464309T1 (sl) 2020-10-30
US20190375779A1 (en) 2019-12-12
HUE051335T2 (hu) 2021-03-01
EA036409B1 (ru) 2020-11-06
SA518400552B1 (ar) 2021-12-08
AU2017273117B2 (en) 2021-02-04
CA3025440A1 (en) 2017-12-07
CL2018003404A1 (es) 2019-04-05
IL263121B (en) 2021-10-31
BR112018074961A2 (pt) 2019-03-12
SG11201810018TA (en) 2018-12-28
JP7025351B2 (ja) 2022-02-24
JP2022051936A (ja) 2022-04-01

Similar Documents

Publication Publication Date Title
EA201892745A1 (ru) Фосфорамидатные производные нуклеозида в качестве противораковых агентов
CY1124055T1 (el) Ετεροκυκλικες ενωσεις ως ανοσοδιαμορφωτες
EA201990221A1 (ru) 1,3-дигидроксифенильные производные, применимые в качестве иммуномодуляторов
CY1120361T1 (el) Αναστολεις 2,3-διοξυγενασης ινδολαμινης (ido)
CY1122074T1 (el) Νεα παραγωγα 3'-δεοξυαδενοσινης του φωσφοραμαδικου εστερα toy 2' και/η 5' aminoξεος ως αντικαρκινικες ενωσεις
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EA201700181A1 (ru) Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
EA201991399A1 (ru) Аминотриазолопиридиновые соединения и их применение в лечении рака
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
EA201692422A1 (ru) Состав, содержащий пролекарство гемцитабина
CL2013002517A1 (es) Compuestos derivados de fosforoamidato de 5-fluoro-2'-desoxiuridina; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso en el tratamiento o profilaxis del cancer.
PH12018500263A1 (en) Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201892769A3 (ru) Сложные диэфиры ациклических нуклеозидфосфонатов
EA202090258A3 (ru) Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar
EA201591925A1 (ru) Терапевтические композиции и их применение
UY37466A (es) N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
EA202190058A1 (ru) Композиции фосфорамидатных производных нуклеозидных лекарственных средств
EA201990400A1 (ru) Соединения и композиции и их применение
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
EA201690388A1 (ru) Новые производные унциаламицина, способы их синтеза и их применение в качестве противоопухолевых агентов
EA201991196A1 (ru) Претерпевшие самосборку диблок-сополимеры, состоящие из pegmema и несущих лекарственное средство полимерных сегментов